Stocks · News reference
Filed: 2026-09-02 AccNo: 0001193125-26-380215 Size: 388 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Attovia Therapeutics reported positive topline results from its Phase 1b study of ATTO-1310, demonstrating sustained IL-31 suppression and rapid itch reduction in patients with chronic pruritus and atopic dermatitis.
Attovia Therapeutics, Inc. announced that its management team will participate in three upcoming investor conferences in November 2026.
Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that
U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.
Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.62) by 5.63 percent. This is a 31.54 percent decrease over losses of $(3.71) per share